Keynote Session III: Precision Medicine – The Analytical Pipeline Behind Patient Remote Blood Sampling

Changes in cellular protein concentrations and isoform expression are dictated by transcriptional, translational, and protein degradation rates and can reflect disease processes. Protein post-translational modifications (PTMs), especially those related to disease processes, add layers of potential functional modulation. Capturing disease proteomic signatures in body fluids like plasma or dried blood may provide insights into underlying disease mechanisms and potential avenues for diagnostic, prognostic, and progression biomarkers. Underlying precision health centers individual’s proteomic signature, especially those which evolve over time will provide physicians with clinically actionable diagnosis. With enhanced adoption of telehealth with the COVID-19 pandemic could increase the integration of semi continuous biochemical blood-based monitoring into the US health care system. Blood components include resident plasma proteins, and proteins from tissue leakage which circulate in response to systemic stimuli and include innate immunity (e.g. cytokine and others). With large scale proteomic analysis of 100-1000s of samples, the biological, environmental, and genetic impact on health and disease signatures should underscore mechanistic and biological variability. We have developed a high throughput robust pipeline from remote sample procurement, shipping, automated sample processing and LC-MSMS methods for targeted discovery and selective pathways (e.g. acute phase). The application of multiple modal pipeline also accommodates for plasma. We deployed remote sampling device to track individuals with COVID-19 as well as patients with mid-risk cardiac diseases and other situations. The application of mass spectrometer from discovery to use in a clinical chemistry lab is essential to this transition. We will discuss the process and quality control behind the sciences in allowing the application of remote sampling into clinical situation. The promise of proteomics and the use of protein-based mass spectrometry in the clinical domain has been widely stated, and although adopt still has a number challenges process for success are being put into place for its operationalization.